Neumora Therapeutics, Inc.
NMRA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001885522
In the last 90 days, Neumora Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 113 institutions reported holding it in 13F filings for Q2 2026, worth $129.2M in total; no superinvestor holds it.
13F holders, Q1 2026
Institutional positions in Neumora Therapeutics, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 114
- +14 vs. Q4 2025
- Shares held
- 70.4M
- +12.0M (+20.6%) vs. Q4 2025
- Total value
- $137.2M
- +$32.7M (+31.3%) vs. Q4 2025
- New holders
- 24
- 34 more added
- Sold out
- 10
- 32 more reduced
2 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NMRA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 113 | $129.2M |
| Q1 2026 | 114 | $137.2M |
| Q4 2025 | 102 | $112.7M |
| Q3 2025 | 93 | $92.2M |
| Q2 2025 | 98 | $41.1M |
| Q1 2025 | 116 | $65.2M |
| Q4 2024 | 135 | $851.6M |
| Q3 2024 | 104 | $907.0M |
| Q2 2024 | 93 | $627.4M |
| Q1 2024 | 88 | $725.4M |
| Q4 2023 | 60 | $744.8M |
| Q3 2023 | 38 | $512.0M |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Neumora Therapeutics, Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Renaissance Technologies LLC | 1,388,998 | $2.71M | 0.00% | −56,904−3.9% | Reduced |
| Johnson & Johnson | 1,849,445 | $3.61M | 0.55% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 2,036,692 | $3.97M | 0.00% | +729,004+55.7% | Added |
| BlackRock, Inc. | 2,054,316 | $4.01M | 0.00% | +29,372+1.5% | Added |
| Lunate Capital Ltd | 2,124,143 | $4.14M | 3.44% | 00.0% | Unchanged |
| ICONIQ Capital, LLC | 2,559,090 | $4.99M | 0.11% | 00.0% | Unchanged |
| Millennium Management LLC | 2,754,854 | $5.37M | 0.00% | −861,660−23.8% | Reduced |
| WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST | 3,309,123 | $6.45M | 0.08% | 00.0% | Unchanged |
| FMR LLC | 3,498,658 | $6.82M | 0.00% | +3890.0% | Added |
| Vanguard Capital Management LLC | 3,891,893 | $7.59M | 0.00% | +3,891,893 | New |
| MIC Capital Management UK LLP | 4,460,700 | $8.70M | 2.47% | 00.0% | Unchanged |
| Perceptive Advisors LLC | 5,104,097 | $9.95M | 0.20% | +5,104,097 | New |
| Softbank Group Corp | 6,090,301 | $11.9M | 0.10% | −339,419−5.3% | Reduced |
| Siren, L.L.C. | 8,497,822 | $16.6M | 0.46% | +2,209,039+35.1% | Added |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −1,083,400−100.0% | Sold out |
| Graham Capital Management, L.P. | 0 | $0 | 0.00% | −191,416−100.0% | Sold out |
| Fred Alger Management, LLC | 0 | $0 | 0.00% | −22,177−100.0% | Sold out |
| Ieq Capital, LLC | 0 | $0 | 0.00% | −13,173−100.0% | Sold out |
| Creative Planning | 0 | $0 | 0.00% | −10,881−100.0% | Sold out |
| Walleye Trading LLC | 0 | $0 | 0.00% | −4,000−100.0% | Sold out |
| Optiver Holding B.V. | 0 | $0 | 0.00% | −592−100.0% | Sold out |
| Daiwa Securities Group Inc. | 0 | $0 | 0.00% | −533−100.0% | Sold out |
| Optima Capital LLC | 0 | $0 | 0.00% | −270−100.0% | Sold out |
| Essential Partners LLC | 0 | $0 | 0.00% | −30−100.0% | Sold out |
| Vanguard Group Inc | – | – | – | – | Not filed |
| Clarius Group, LLC | – | – | – | – | Not filed |